Postinduction, median nadir serum asparaginase activity was similar in patients receiving either drug, suggesting a need for dosing optimization.
A retrospective cohort study from St Jude Children’s Research Hospital sought to determine how long-term effects of treatment have evolved for survivors of pediatric ALL.
New possible mechanisms of resistance to CD19 CAR-T were put forth for B-cell acute lymphoblastic leukemia.
Variability in minimal residual disease measurement techniques inhibits the ability to compare data across laboratories and clinical trials.
Patients with rapid early response demonstrated increased event-free and overall survival when receiving augmented postinduction intensification regimens.
CAR-T–related neurotoxicity was found to be associated with the presence of cytokine release syndrome.
An investigation of a large performance improvement clinical database revealed that most individuals receiving CAR-T have diagnoses of ALL or large B-cell lymphoma.
Medicare coverage has been announced for Adaptive Biotechnologies’ clonoSEQ® next-generation sequencing assay for the detection of minimal residual disease (MRD) after treatment for multiple myeloma or B-cell acute lymphoblastic leukemia (ALL) — a key step toward its use for patient care in cancer clinics in the United States.1,2The FDA announced regulatory approval for the assay…
Clinical outcomes of patients with hypodiploid B-ALL are poor compared with those with B-ALL not characterized by hypodiploidy, according to researchers.
Patients with B-ALL may benefit from sequential treatment with CD19 CAR-T therapy and anti-CD19 bispecific T-cell engager therapy regardless of sequence, according to a case study report.
